Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2020 Mar 16

PMID 32172359

Citations 14

Authors

Nicole Kucine

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Myeloproliferative neoplasms are traditionally seen in older adults, making them poorly understood in younger patients. Clinical presentation, genetic landscape, outcomes, and best management practices are inadequately described in this group. Over the past decade, more research has focused on younger patients, and this paper seeks to review and describe the current status of the field.

Recent Findings: A recent review analyzed the available pediatric MPN literature and highlighted the paucity of published data. Pediatric patients showed lower rates of the common mutations found in adults, thrombotic events, and disease transformation to myelofibrosis and acute leukemia. A number of centers have recently shared their experience with young adult patients. Better survival outcomes were confirmed for young adult patients compared to older patients. There is still much to learn about myeloproliferative neoplasms in pediatric and young adult patients, but currently available data showing better outcomes is reassuring.

Citing Articles

[Advances in the diagnosis and treatment of thrombocytosis in children].

Xu Y, Hu Q Zhongguo Dang Dai Er Ke Za Zhi. 2025; 27(2):236-241.

PMID: 39962789 PMC: 11838038. DOI: 10.7499/j.issn.1008-8830.2408066.

Polycythemia vera and essential thrombocythemia in children, still a challenge for pediatricians.

Picard A, Bayart S, Deparis M, De Maricourt C, Haro S, Jourdain A Eur J Pediatr. 2025; 184(2):173.

PMID: 39903357 PMC: 11794414. DOI: 10.1007/s00431-025-05993-1.

Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults.

Ozygala A, Rokosz-Mierzwa J, Widz P, Skowera P, Wilinski M, Styka B Cancers (Basel). 2024; 16(23).

PMID: 39682300 PMC: 11640741. DOI: 10.3390/cancers16234114.

Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.

Fu R, Dong H, Gu W, Meng K, Sun T, Liu X Leukemia. 2024; 39(1):155-165.

PMID: 39375514 DOI: 10.1038/s41375-024-02432-2.

Myeloproliferative neoplasms: young patients, current data and future considerations.

Sobas M, Ianotto J, Kiladjian J, Harrison C Ann Hematol. 2024; 103(9):3287-3291.

PMID: 39110200 DOI: 10.1007/s00277-024-05920-8.

References

Kucine N, Al-Kawaaz M, Hajje D, Bussel J, Orazi A . Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. Br J Haematol. 2018; 185(1):136-139. PMC: 6239998. DOI: 10.1111/bjh.15386. View

Pizzi M, Silver R, Barel A, Orazi A . Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015; 28(10):1315-23. DOI: 10.1038/modpathol.2015.93. View

Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R . Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32(5):1057-1069. PMC: 5986069. DOI: 10.1038/s41375-018-0077-1. View

An W, Wan Y, Guo Y, Chen X, Ren Y, Zhang J . CALR mutation screening in pediatric primary myelofibrosis. Pediatr Blood Cancer. 2014; 61(12):2256-62. DOI: 10.1002/pbc.25211. View

Pardanani A, Levine R, Lasho T, Pikman Y, Mesa R, Wadleigh M . MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108(10):3472-6. DOI: 10.1182/blood-2006-04-018879. View

Yogarajah M, Tefferi A . Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. Mayo Clin Proc. 2017; 92(7):1118-1128. DOI: 10.1016/j.mayocp.2017.05.010. View

Navid F, Herzog C, Sandoval J, Daryani V, Stewart C, Gattuso J . Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. Pediatr Blood Cancer. 2016; 63(7):1207-13. PMC: 4877209. DOI: 10.1002/pbc.25983. View

Barbui T . How to manage children and young adults with myeloproliferative neoplasms. Leukemia. 2012; 26(7):1452-7. DOI: 10.1038/leu.2012.12. View

Ginzburg Y, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R . Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018; 32(10):2105-2116. PMC: 6170398. DOI: 10.1038/s41375-018-0207-9. View

10.

Low M, Farrell A, Biggs B, Pasricha S . Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials. CMAJ. 2013; 185(17):E791-802. PMC: 3832580. DOI: 10.1503/cmaj.130628. View

11.

Randi M, Bertozzi I, Putti M . Contemporary management of essential thrombocythemia in children. Expert Rev Hematol. 2019; 12(5):367-373. DOI: 10.1080/17474086.2019.1602034. View

12.

Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J . Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2017; 97(1):109-121. DOI: 10.1007/s00277-017-3165-9. View

13.

Stein B, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D . Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2012; 54(9):1989-95. DOI: 10.3109/10428194.2012.759656. View

14.

Ianotto J, Curto-Garcia N, Lauermanova M, Radia D, Kiladjian J, Harrison C . Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019; 104(8):1580-1588. PMC: 6669170. DOI: 10.3324/haematol.2018.200832. View

15.

Liberek A, Luczak G, Korzon M, Szlagatys-Sidorkiewicz A, Bako W, Gora-Gebka M . Tolerance of interferon-alpha therapy in children with chronic hepatitis B. J Paediatr Child Health. 2004; 40(5-6):265-9. DOI: 10.1111/j.1440-1754.2004.00361.x. View

16.

Ishida H, Miyajima Y, Hyakuna N, Hamada S, Sarashina T, Matsumura R . Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey. EJHaem. 2022; 1(1):86-93. PMC: 9175656. DOI: 10.1002/jha2.39. View

17.

Harrison C, Robinson S . Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am. 2011; 25(2):261-75, vii. DOI: 10.1016/j.hoc.2011.01.008. View

18.

Nangalia J, Green T . The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2015; 2014(1):287-96. DOI: 10.1182/asheducation-2014.1.287. View

19.

Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B . Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015; 29(6):1344-9. DOI: 10.1038/leu.2015.87. View

20.

Szuber N, Vallapureddy R, Penna D, Lasho T, Finke C, Hanson C . Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018; 93(12):1474-1484. DOI: 10.1002/ajh.25270. View